  |  |  |  |
Tuesday, 10 August 2010
Marshall Edwards oppoints oncologist Christine White to its Board
More news
|
| 
|
|  |
 |
Current News
Promensil produces significant cholesterol reduction in women - new study
Monday, 17 June 2002
A research study reported at the 10th World Congress on the Menopause in Berlin, revealed a statistically significant fall in blood cholesterol in women using Promensil.
This finding adds to the established health benefits for women taking the red clover isoflavone supplement, Promensil.
The study, reported by Dr Arturo Jeri of the Institute of Gynaecology and Reproduction, Lima, Peru, was a double blind placebo controlled trial involving 100 menopausal women selected on the basis of having moderately elevated blood cholesterol. The primary goal was to determine whether blood cholesterol levels were reduced following three months of Promensil treatment.
The results revealed a statistically significant fall in blood cholesterol, particularly in LDL or “bad” cholesterol, by approximately 10 per cent, and a significant improvement in the ratio of HDL “good” cholesterol to LDL cholesterol in the treated group compared with placebo. No adverse effects were reported.
These data build on previous findings of a statically significant improvement in the acute symptoms of menopause such as hot flushes among women using Promensil.
It is well known that as women age and estrogen levels decline, their so-called “good” HDL cholesterol levels fall. Thus women over 55 are much more likely to die of heart attack or other cardiovascular incidents than men of the same age. It has been estimated that 30 per cent, or more than half a million Australian women over 60, are likely to die from heart disease or stroke.
Novogen’s Research Director, Professor Alan Husband, said “These research findings indicated that in addition to managing acute symptoms of menopause, long term use of Promensil would potentially protect women against cholesterol deposition in the arteries, a major cause of cardiovascular disease in women in this age group.
“The magnitude of the reduction in cholesterol observed in this study could translate to a possible 20 per cent reduction in risk of cardiovascular disease,” Professor Husband said.
“The study confirms that Promensil is able to deliver some of the benefits of HRT, without the adverse side effects.
“Considered in the light of other published studies accumulated over the past three years showing improved arterial elasticity and bone density and reduced breast densities in menopausal women taking Promensil, these latest clinical trial data provide convincing evidence that red clover isoflavones have a beneficial role to play in maintaining health and wellbeing.
“Many women are turning away from some prescription therapies to maintain health because of the suspected risks of breast and uterine cancer, breakthrough bleeding, a return of hot flushes and weight gain,” Professor Husband added.
Promensil contains a standardised, proprietary formulation of isoflavones that delivers an optimal estrogenic outcome when consumed by menopausal women.
Promensil is available over-the-counter nationally in pharmacies, health food stores and selected supermarkets in one month (30 tablets) and three month (90 tablets) packs.
|
|
|
|
